These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

3308 related items for PubMed ID: 26159280

  • 1. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Traussnigg S, Kienbacher C, Halilbasic E, Rechling C, Kazemi-Shirazi L, Hofer H, Munda P, Trauner M.
    Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
    [Abstract] [Full Text] [Related]

  • 2. PNPLA3 genotype increases susceptibility of nonalcoholic steatohepatitis among obese patients with nonalcoholic fatty liver disease.
    Tai CM, Huang CK, Tu HP, Hwang JC, Chang CY, Yu ML.
    Surg Obes Relat Dis; 2015; 11(4):888-94. PubMed ID: 25240529
    [Abstract] [Full Text] [Related]

  • 3. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients.
    Ong JP, Elariny H, Collantes R, Younoszai A, Chandhoke V, Reines HD, Goodman Z, Younossi ZM.
    Obes Surg; 2005 Mar; 15(3):310-5. PubMed ID: 15826462
    [Abstract] [Full Text] [Related]

  • 4. Therapies in non-alcoholic steatohepatitis (NASH).
    Oseini AM, Sanyal AJ.
    Liver Int; 2017 Jan; 37 Suppl 1(Suppl 1):97-103. PubMed ID: 28052626
    [Abstract] [Full Text] [Related]

  • 5. Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes.
    Ahmed A, Wong RJ, Harrison SA.
    Clin Gastroenterol Hepatol; 2015 Nov; 13(12):2062-70. PubMed ID: 26226097
    [Abstract] [Full Text] [Related]

  • 6. Nonalcoholic Fatty Liver Disease--The Clinician's Perspective.
    Agrawal S, Duseja A.
    Trop Gastroenterol; 2014 Nov; 35(4):212-21. PubMed ID: 26349165
    [Abstract] [Full Text] [Related]

  • 7. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
    Kanda T, Goto T, Hirotsu Y, Masuzaki R, Moriyama M, Omata M.
    Int J Mol Sci; 2020 Feb 23; 21(4):. PubMed ID: 32102237
    [Abstract] [Full Text] [Related]

  • 8. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Wu J.
    Oncotarget; 2016 Jul 05; 7(27):42762-42776. PubMed ID: 27072576
    [Abstract] [Full Text] [Related]

  • 9. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y, Sugimoto K, Inui H, Fukusato T.
    World J Gastroenterol; 2015 Apr 07; 21(13):3777-85. PubMed ID: 25852263
    [Abstract] [Full Text] [Related]

  • 10. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
    Perumpail RB, Wong RJ, Ahmed A, Harrison SA.
    Dig Dis Sci; 2015 Oct 07; 60(10):3142-8. PubMed ID: 26250831
    [Abstract] [Full Text] [Related]

  • 11. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y, Fukusato T.
    World J Gastroenterol; 2014 Nov 14; 20(42):15539-48. PubMed ID: 25400438
    [Abstract] [Full Text] [Related]

  • 12. The epidemiology of nonalcoholic fatty liver disease in adults.
    Clark JM.
    J Clin Gastroenterol; 2006 Mar 14; 40 Suppl 1():S5-10. PubMed ID: 16540768
    [Abstract] [Full Text] [Related]

  • 13. Prevalence and Predictors of Non-Alcoholic Fatty Liver Disease in Morbidly Obese South Indian Patients Undergoing Bariatric Surgery.
    Praveenraj P, Gomes RM, Kumar S, Karthikeyan P, Shankar A, Parthasarathi R, Senthilnathan P, Rajapandian S, Palanivelu C.
    Obes Surg; 2015 Nov 14; 25(11):2078-87. PubMed ID: 25835982
    [Abstract] [Full Text] [Related]

  • 14. Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease.
    Liew PL, Lee WJ, Lee YC, Wang HH, Wang W, Lin YC.
    Obes Surg; 2006 Dec 14; 16(12):1584-93. PubMed ID: 17217634
    [Abstract] [Full Text] [Related]

  • 15. Metabolic Syndrome: Nonalcoholic Fatty Liver Disease.
    Williams T.
    FP Essent; 2015 Aug 14; 435():24-9. PubMed ID: 26280342
    [Abstract] [Full Text] [Related]

  • 16. Management and diagnosis of fatty liver disease.
    Schneier AT, Citti CC, Dieterich DT.
    Expert Rev Gastroenterol Hepatol; 2015 May 14; 9(5):671-83. PubMed ID: 25716275
    [Abstract] [Full Text] [Related]

  • 17. Utility of the ELF Test for Detecting Steatohepatitis in Morbid Obese Patients with Suspicion of Nonalcoholic Fatty Liver Disease.
    López IC, Aroca FG, Bernal MDF, Mompeán JAL, Bernal ÁB, Martínez AMH, Barba EM, Velasco JAN, Paricio PP.
    Obes Surg; 2017 Sep 14; 27(9):2347-2353. PubMed ID: 28229316
    [Abstract] [Full Text] [Related]

  • 18. Clinical characteristics and management of patients with nonalcoholic steatohepatitis in a real-world setting: analysis of the Ipsos NASH therapy monitor database.
    Shelley K, Articolo A, Luthra R, Charlton M.
    BMC Gastroenterol; 2023 May 19; 23(1):160. PubMed ID: 37208593
    [Abstract] [Full Text] [Related]

  • 19. Nonalcoholic fatty liver disease: from steatosis to cirrhosis.
    Farrell GC, Larter CZ.
    Hepatology; 2006 Feb 19; 43(2 Suppl 1):S99-S112. PubMed ID: 16447287
    [Abstract] [Full Text] [Related]

  • 20. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies.
    Stefan N, Häring HU, Cusi K.
    Lancet Diabetes Endocrinol; 2019 Apr 19; 7(4):313-324. PubMed ID: 30174213
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 166.